The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Sternberg, D. E.
* Articles by Bunney, W. E.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Sternberg, D. E.
* Articles by Bunney, W. E., Jr

Am J Psychiatry 1981; 138:1045-1050
Copyright © 1981 by American Psychiatric Association


REGULAR ARTICLES

The effect of pimozide on CSF norepinephrine in schizophrenia

DE Sternberg, DP van Kammen, CR Lake, JC Ballenger, SR Marder and WE Bunney Jr

The authors measured CSF norepinephrine concentrations in drug-free schizophrenic patients with and without probenecid administration and in drug-free normal control subjects. Schizophrenic patients had significantly higher baseline norepinephrine values. The dopamine metabolite homovanillic acid correlated significantly with norepinephrine. During chronic treatment with the neuroleptic pimozide, patients' norepinephrine levels were significantly decreased. The pimozide-induced decrease in norepinephrine, as well as the percent decrease, correlated significantly with the patients' decrease in global psychosis. These data are consistent with recent reports of elevated concentrations of norepinephrine in specific brain areas of schizophrenic patients, and they support a role for norepinephrine metabolism in the pharmacological effects of antipsychotic drugs.


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
D.G.C. Owens, P.E. Harrison-Read, and E. C. Johnstone
L-dopa helps positive but not negative features of neuroleptic-insensitive chronic schizophrenia
J Psychopharmacol, January 1, 1994; 8(4): 204 - 212.
[Abstract] [PDF]


Home page
ScienceHome page
D. Sternberg, D. VanKammen, P Lerner, and W. Bunney
Schizophrenia: dopamine beta-hydroxylase activity and treatment response
Science, June 25, 1982; 216(4553): 1423 - 1425.
[Abstract] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1981 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org